A targeted approach for thetreatment of hypertension
At Mineralys Therapeutics we aim to redefine hypertension diagnosis, management and treatment.
The ProblemHigh blood pressure costs the United States $131 billion each year.
Controlling hypertension is critical to reducing cardiovascular and renal disease; yet over 50% of hypertension patients fail to achieve control.
While the blood pressure goal continues to go down, there have been no innovative treatments for hypertension developed in over ten years. Rather, it has relied on "trial, fail and add". This approach leads to polypharmacy, adverse events and poor overall compliance and adherence.